Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N. Allan, Jennifer R. Brown, Jeff P. Sharman et al.|Haematologica|2021Cited by 37